glp 1 sleep For Professionals: GLP-1 Therapy with Wesper Therapeutic Potential of Glucagon-like Peptide-1

The catch with oral BPC-157

Natalie H

Key Results Semaglutide vs Sitagliptin HR 0.58 (95% CI, 0.510.65) 42% lower risk 1-yr absolute risk: 5.5% vs 8.6% NNT 31 Tirzepatide vs Sitagliptin HR 0.42 (95% CI, 0.310.57) 58% lower risk 1-yr absolute risk: 3.6% vs 7.5% NNT 26 Tirzepatide vs Semaglutide HR 0.86 (95% CI, 0.701.06) no statistically significant difference Safety: No excess signal for GI, infections, or serious AEs across GLP-1/dual arms

Usual limitations of the studies concerning risk factors for DPN are: predominance of cross-sectional studies, inconsistent diagnostic criteria of DPN, high statistical heterogenity, inadequate assessment of risk factor duration and missclassification of outcomes

NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis